GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Future 3-5Y Total Revenue Growth Rate

Immunotech Biopharm (HKSE:06978) Future 3-5Y Total Revenue Growth Rate : N/A (As of Jun. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate is N/A.


Competitive Comparison of Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Immunotech Biopharm  (HKSE:06978) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Immunotech Biopharm Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Yan Kaijing 2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Cao Longxiang 2201 Interest of corporation controlled by you
Cao Fei 2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Yan Xijun 2501 Other
Wu Naifeng 2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited 2501 Other
Li Yunhui 2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
China Resources Company Limited 2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines